Latest Stories
Uncategorized
Zealand Pharma Partners With AI Biotech Generate on Next-Generation Weight-Loss Protein Drugs
Zealand Pharma has linked up with AI protein design company Generate Biomedicines to develop multispecific protein therapies for weight loss, extending the Danish company's pipeline of obesity treatments.
Uncategorized
OpenAI Acquires Orchestra Bio, Folding Drug-Program AI Agents Into Its Rosalind Life Sciences Suite
OpenAI announced on October 20 that it acquired Orchestra Bio, a startup whose AI agents track drug-development timelines for biopharma teams, folding the technology into its Rosalind life sciences suite already used by Moderna and Novo Nordisk.
Uncategorized
Anthropic Buys One-Person Biotech Mithril Medicine, Opens Claude-Run Drug Pipeline With Six Pharma Partners
Anthropic announced on October 27 that it acquired Mithril Medicine, a biotech founded and run by a single scientist, and disclosed six separate pharma collaborations as it moves from selling AI tools to running its own Claude-assisted drug programs.
Uncategorized
Suki Raises $90 Million Series E as Its AI Medical Scribe Hits 450 Health System Customers
Suki closed a $90 million Series E led by Healthier Capital, scaling its AI medical-scribe platform to roughly 450 customers and projecting as much as $80 million in 2026 revenue, as ambient-documentation tools become one of the most adopted categories in clinical AI.
In-Depth
Uncategorized
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Its Hospital Diagnostic AI
Aidoc closed a $150 million Series E led by Goldman Sachs Alternatives, pushing its total funding past $500 million as the hospital imaging-AI company pivots from single-disease alerts toward a broader clinical foundation model.
Uncategorized
AstraZeneca Pays Up to $1.5 Billion for insitro’s Machine-Learning Drug Target Platform
AstraZeneca is paying insitro up to $1.5 billion to use machine learning to find and validate new drug targets, the latest entry in a pharma AI dealmaking spree that topped $47 billion in licensing agreements in just the first half of 2026.
Uncategorized
Takeda Signs Up to $1.7 Billion AI Deal With Iambic Therapeutics for Small-Molecule Drug Design
Takeda signed a multi-year AI drug discovery collaboration with Iambic Therapeutics worth up to $1.7 billion in milestones, giving Takeda access to Iambic's NeuralPLexer protein-ligand prediction model for small-molecule programs in oncology and inflammatory disease.
Uncategorized
FDA Seeks Public Comment on Regulating Generative AI Medical Devices as Cleared AI Tools Top 700
The FDA's Digital Health Center of Excellence opened a public comment period, closing October 19, on a discussion paper proposing a risk-proportionate framework for regulating generative AI medical devices.
Uncategorized
GSK Widens AI Drug Design Deal With Chai Discovery After In-House Scientists Validate Its Models
GSK expanded its collaboration with Chai Discovery in October after its own scientists independently tested and validated the AI startup's molecular design models, a notable vote of confidence in Chai's approach.
